Late outcomes of ST-elevation myocardial infarction treated by pharmaco-invasive or primary percutaneous coronary

Javeria Jamal1,2,3, Hanan Idris1,4,5, Amir Faour1,3

  • 1Department of Cardiology, Elizabeth Street, Liverpool Hospital, Sydney, NSW 2170, Australia.

European Heart Journal
|December 2, 2022
PubMed

Insights

Pharmaco-invasive percutaneous coronary intervention (PI-PCI) offers better outcomes than late primary PCI (pPCI) for ST-elevation myocardial infarction (STEMI) patients. PI-PCI should be considered when timely pPCI is not feasible, even if rescue PCI is needed.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Acute Coronary Syndromes

Background:

  • Pharmaco-invasive percutaneous coronary intervention (PI-PCI) is recommended for ST-elevation myocardial infarction (STEMI) patients unable to undergo timely primary PCI (pPCI).
  • This study compares late outcomes of PI-PCI with timely and late pPCI.

Purpose of the Study:

  • To evaluate the late outcomes of a pharmaco-invasive strategy versus primary PCI in STEMI patients.
  • To determine if PI-PCI offers a survival benefit compared to delayed pPCI.

Main Methods:

  • Retrospective analysis of 2091 STEMI patients undergoing PCI between October 2003 and March 2014.
  • Patients were categorized into timely pPCI, late pPCI, and PI-PCI (scheduled or rescue).
  • Propensity matching was used to compare mortality rates at 3 years.

Main Results:

  • 3-year mortality was significantly lower with PI-PCI (6.2%) compared to pPCI (11.1%) (P < 0.01).
  • Late pPCI was associated with higher mortality (20.2%) than timely pPCI (6.7%).
  • Adjusted analyses showed lower mortality for scheduled PCI vs. rescue PCI, and both were better than late pPCI.

Conclusions:

  • A pharmaco-invasive strategy is associated with better survival outcomes than late primary PCI in STEMI patients.
  • PI-PCI should be considered when delays to primary PCI are anticipated.
  • Even with a need for rescue PCI in a third of cases, PI-PCI demonstrates superior outcomes to late pPCI.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
22
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
56
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
19
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
22
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
34
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
20